Clinical Trial

Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure

Study acronym: CAPU RISE
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this Phase I non-therapeutic trial is to examine the neurological effects of cannabis on stress reactivity and inhibition in healthy cannabis users. We expect differences between high ratio CBD:THC cannabis oil, low ratio CBD:THC cannabis oil, and/or placebo on outcome measures.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-02-18; most recent amendment 2026-02-28.
Status change: Recruiting → Active, Not Recruiting 2026-02-28
Status change: Not Yet Recruiting → Recruiting 2023-10-20
Trial Details
NCT Number NCT05261321
Lead Sponsor University of British Columbia
Conditions Healthy
Enrollment 20 participants
Start Date 2022-10-15
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-03